Drug Profile
LIQ 001
Alternative Names: LIQ001Latest Information Update: 14 Dec 2015
Price :
$50
*
At a glance
- Originator Liquidia Technologies
- Class Influenza virus vaccines; Pancreatic enzymes; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 14 Dec 2015 Phase I/II development is ongoing in USA
- 01 Dec 2011 Liquidia Technologies completes its phase I/II trial for Influenza virus infections (Prevention, In adult and elderly volunteers) in USA (NCT01224262)
- 03 Jan 2011 Liquidia Technologies completes enrolment in its phase I/II trial for Influenza virus infections (Prevention, In adult and elderly volunteers) in USA